SGLT-2 Inhibitors and Metabolic Outcomes: A Primary Data Study Exploring the Microbiota–Diabetes Connection
Treatment with sitagliptin and empagliflozin led to improved glycemic outcomes and partial restoration of gut microbial balance in T2DM patients. Empagliflozin showed superior efficacy in modulating both glycemia and dysbiosis.
Authors
- Cristian Guja (ORCID: https://orcid.org/0000-0002-8703-0522)
- Sorina Ispas (ORCID: https://orcid.org/0009-0000-3401-1232)
- Antoanela Curici (ORCID: https://orcid.org/0009-0002-2858-1970)
- Rucsandra Elena Dănciulescu Miulescu
- Anca Pantea Stoian (ORCID: https://orcid.org/0000-0003-0555-526X)
- Viorel Jinga (ORCID: https://orcid.org/0000-0001-7632-5328)
- Andreea Nelson Twakor (ORCID: https://orcid.org/0000-0002-5872-4381)
- Nicoleta Mihaela Mindrescu
Institutions
- Ovidius University (RO)
- Carol Davila University of Medicine and Pharmacy (RO)
- Clinical Emergency Hospital Bucharest (RO)
Publication Details
- Journal
- Metabolites
- Published
- 2025-06-18
- DOI
- https://doi.org/10.3390/metabo15060411
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 3.88